home / stock / fh:cc / fh:cc quote
Last: | $0.18 |
---|---|
Change Percent: | 5.88% |
Open: | $0.18 |
Close: | $0.18 |
High: | $0.185 |
Low: | $0.17 |
Volume: | 7,583 |
Last Trade Date Time: | 05/06/2022 04:52:04 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.18 | $0.18 | $0.18 | $0.185 | $0.17 | 7,583 | 05-06-2022 |
$0.17 | $0.18 | $0.17 | $0.18 | $0.17 | 6,806 | 05-05-2022 |
$0.175 | $0.19 | $0.175 | $0.195 | $0.175 | 37,983 | 05-04-2022 |
$0.18 | $0.16 | $0.18 | $0.18 | $0.14 | 82,937 | 05-03-2022 |
$0.155 | $0.16 | $0.155 | $0.16 | $0.155 | 4,980 | 05-02-2022 |
$0.16 | $0.155 | $0.16 | $0.16 | $0.155 | 7,400 | 04-29-2022 |
$0.155 | $0.155 | $0.155 | $0.155 | $0.15 | 5,518 | 04-28-2022 |
$0.155 | $0.155 | $0.155 | $0.155 | $0.155 | 27,698 | 04-27-2022 |
$0.15 | $0.15 | $0.15 | $0.15 | $0.145 | 111,913 | 04-26-2022 |
$0.145 | $0.15 | $0.145 | $0.15 | $0.145 | 138,871 | 04-25-2022 |
$0.15 | $0.15 | $0.15 | $0.15 | $0.15 | 24,200 | 04-22-2022 |
$0.145 | $0.15 | $0.145 | $0.15 | $0.145 | 120,262 | 04-21-2022 |
$0.15 | $0.135 | $0.15 | $0.15 | $0.135 | 70,461 | 04-20-2022 |
$0.135 | $0.13 | $0.135 | $0.135 | $0.13 | 8,211 | 04-19-2022 |
$0.13 | $0.14 | $0.13 | $0.14 | $0.125 | 37,506 | 04-18-2022 |
$0.14 | $0.17 | $0.14 | $0.17 | $0.135 | 100,070 | 04-15-2022 |
$0.14 | $0.17 | $0.14 | $0.17 | $0.135 | 99,951 | 04-14-2022 |
$0.16 | $0.11 | $0.16 | $0.19 | $0.11 | 160,245 | 04-13-2022 |
$0.11 | $0.11 | $0.11 | $0.115 | $0.11 | 58,163 | 04-12-2022 |
$0.1 | $0.115 | $0.1 | $0.115 | $0.1 | 66,550 | 04-11-2022 |
News, Short Squeeze, Breakout and More Instantly...
FILAMENT HEALTH CORP. Company Name:
FH:CC Stock Symbol:
AQNC Market:
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...
FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER Canada NewsWire VANCOUVER, BC , June 3, 2024 /CNW/ - Filament Health Corp. (OTCQB:...